Table 4.
Cause of discontinuation of SGLT2i or GLP-1RA
| Variable | No. (%) |
|---|---|
| SGLT2i | |
| Discontinuation of SGLT2ia | 82/482 (17.0) |
| Patient factor; complaint of | 10/82 (12.2) |
| Dehydration or weight reduction | 5 (6.1) |
| Genital problem | 1 (1.2) |
| Polyuria | 1 (1.2) |
| Glucose control (hyper/hypo-glycemia) | 1 (1.2) |
| Others | 2 (2.4) |
| Treatment factor; evidence for | 22/82 (26.8) |
| Uncontrolled glucose level | 16 (19.5) |
| Acute kidney injury | 2 (2.4) |
| Urinary tract/genital infection | 1 (1.2) |
| Complication of diabetes | 1 (1.2) |
| Diabetic ketoacidosis | 0 |
| GLP-1RA | |
| Discontinuation of GLP-1RAb | 15/29 (51.7) |
| Patient factor; complaint of | 3/15 (20.0) |
| Gastrointestinal problem | 1 (6.7) |
| Injection site problem | 1 (6.7) |
| Glucose control (hyper/hypo-glycemia) | 0 |
| Others | 1 (6.7) |
| Treatment factor; evidence for | 4/15 (26.7) |
| Uncontrolled glucose level | 3 (20.0) |
| Complication of diabetes | 1 (6.7) |
| Gastropathy | 0 |
SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1RA, glucagon-like peptide 1 receptor agonist.
a
In case of the patients initiating SGLT2i after event (n=482, 91.3%),
b
In case of the patients initiating GLP-1RA after event (n=29, 82.8%).